Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BEA 2180 BR in Healthy Males
NCT02254720Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of bea 2180 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of participants with abnormal findings in physical examination, Number of participants with clinically significant changes in vital signs and 4 more. Started Sep 2006; status: completed.
02
Drugs
bea 2180
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02254720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254720.